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SPRING 201910
ancer is a deadly disease affecting and 
killing many people every year. For 2019, 
the estimated number of new cancer cases 
exceeds 1.5 million, and the estimated number 
of deaths caused by cancer exceeds six-hundred 
thousand.1 Treatments for cancer certainly exist; 
although current treatments are often costly and are 
not always effective in the long-run. The treatments 
also come with side effects often associated with 
the destruction of healthy, noncancerous cells. 
The expansion of alternatives for treating cancer 
is a constant objective for the medical community, 
and researchers are experimenting with many new 
solutions in order to provide new opportunities to treat 
cancer. One potential treatment in development is 
snake venom, a substance that is normally poisonous 
to humans in its unmodified form.
 Although snake venom as a whole can be 
harmful to humans, it is composed of many different 
proteins, enzymes, and carbohydrates. If the different 
molecules constituting the venom are extracted and 
isolated, the individual molecules can provide benefits 
for humans without the harmful effects of the entire 
venom. For example, the drug captopril is derived 
from snake venom and treats high blood pressure and 
heart failure. As long as the entire venom is not used, 
the separate components can elicit healthy effects in 
humans. In the 1940s, researchers began isolating 
enzymes and non-enzyme proteins from snake venom 
and experimented with the proteins for effects on 
tumor cells. Clinical testing with the venom became 
more prevalent from the 1960s onward.2, 3
 The proteins in snake venom harbor a variety 
of cancer-
fighting characteristics. 
One such type of protein is the disintegrin. 
Disintegrins are non-enzymatic proteins found 
in snake venom and inhibit angiogenesis, the 
development of new blood vessels. Angiogenesis 
allows tumor cells to invade nearby healthy tissue and 
metastasize. Treatment with disintegrins has been 
shown to suppress the spread of tumors due to the 
antiangiogensis activity of disintegrins.3 
L-amino acid oxidases (LAAOs) are enzymatic 
proteins found in snake venom and demonstrate 
anti-tumor effects. LAAO converts L-amino acid to 
alpha-keto acid and releases the byproducts ammonia 
and hydrogen peroxide. Hydrogen peroxide is a major 
proposed mechanism of LAAO-induced toxicity, as it 
can act as reactive oxygen species (ROS) that can 
diffuse into cancer cells and cause cell death. Studies 
have shown that the effects of ROS are more likely to 
harm cancer cells than normal cells, possibly due to 
the higher metabolic activity present in cancer cells. 
The higher metabolic activity leads to higher levels 
of ROS in cancer cells; hence, the cancer cells are 
more susceptible to further increases in ROS levels 
than normal cells. The evidence of selectivity of LAAO 
activity towards cancer cells is beneficial for cancer 
therapy, as the enzyme does not seem to have a high 
potential to harm healthy cells.4
Metalloproteases (MPs) are another group of enzymes 
derived from the venom and can also exhibit anti-
tumor activity.5 One type of MP, known as jarahagin 
(produced by the species Bothrops jararaca), has 
demonstrated cytotoxic effects on melanoma cells, 
as well as inhibition of cancer cell adhesion.6 Cell 
adhesion contributes to tumor spread; thus, by 
inhibiting adhesion, jarahagin can prevent metastasis, 
which is the spread of cancer to a secondary site. 
Phospholipase A2 (PLA2) is another enzyme 
belonging 
to snake 
venom and has 
demonstrated cytotoxic and 
antiangiogenesis effects.5
 Lectins (proteins that bind to sugars) belonging 
to snake venom have been shown to inhibit the 
growth of certain types of cancer cells, such as renal 
and pancreatic cancer cells.5 The proteins have 
also demonstrated cytotoxic activity. In a particular 
experiment, the lectin B1L, belonging to Bothrops 
leucurus venom, was tested and induced apoptosis on 
a variety of cancer cells, including myeloid leukemia 
cells, lung carcinoma, and larynx carcinoma cells. 
Furthermore, healthy cells were not harmed by the 
protein.7 Thus, snake venom lectins can be especially 
helpful in treating certain types of cancer. 
 The process of collecting the venom and 
determining its effects on cancer takes multiple 
steps. The species of snake from which the venom 
is collected depends on the proteins of interest, as 
the type of venom varies among species. It may be 
easier to collect venom in the summer as opposed 
to the winter, as the venom is more liquefied in the 
summer.8 Once the species is identified and captured, 
the snake must be kept in conditions suitable for living. 
A snake can die when kept in conditions unlike its 
natural habitat, and high occurrences of snake deaths 
could shift a vulnerable species closer to becoming 
endangered.2 Once the venom is collected, the 
proteins must be isolated using various purification 
techniques, such as size-exclusion, ion exchange, and 
affinity chromatography. Edman sequencing can be 
used to determine the sequences of small proteins, if 
necessary.9 Once the individual proteins of the venom 
are identified and isolated, researchers can test the 
effects of the proteins on cancer cell activity. 
 The isolation and utilization of snake venom 
components is a valuable cancer-fighting technique 
but is not without its flaws. The immune system can 
possibly react to foreign proteins injected into the 
bloodstream. Immunosuppression may help prevent 
rejection of the proteins by the immune system, but 
would also render the body vulnerable to infectious 
agents. Encapsulation of the proteins in nanocarriers 
for slow, controlled release of the proteins may help 
prevent adverse reactions by the immune system. 
The technique of encapsulation, however, has not 
fully been mastered and is currently in development.3, 
10 Furthermore, the mechanisms of action of many 
cancer-fighting proteins have not yet been confirmed, 
which is why many of these proteins are not yet 
available for purchase from pharmacies.11 Until the 
exact behavior of the snake venom components 
are made certain, there is no guarantee that these 
proteins cannot destroy healthy, noncancerous cells. 
Although many of the proteins have demonstrated 
selectivity towards tumor cells in experiments, further 
research should be done to confirm the abilities of 
these molecules to discriminate between cancerous 
and healthy cells and to determine potential methods 
to circumvent any possibility of the proteins harming 
healthy cells. 
 Snake venom as a treatment for cancer is 
promising and could be an effective alternative to 
current treatments. Whether or not the use of snake 
venoms would be more cost effective or less painful 
than current treatments has not yet been confirmed, 
as the treatment is not a common practice. Further 
research on the behavior of these proteins and on 
potential costs of treating cancer patients with the 
venom should provide more insight about the value of 
the treatment. In the future, when more information is 
made available, snake venom could potentially serve 
as an incredibly valuable alternative to current cancer 
treatments. 
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